Donald Trump: What medtech’s top executives are saying

February 3, 2017 By Chris Newmarker

C.R. Bard CEO Timothy Ring [Image courtesy of C.R. Bard]

“We were told, there were [millions of] uninsured people in the U.S. and the device industry was going to get a windfall. And as a result, we were forced to pay a 2.3% tax to pay for that. Well, that didn’t happen. We didn’t get the windfall, and the other assumption was we would be able to pass down to our customers, and that didn’t happen. So we didn’t notice a big increase at all really in our volumes on the way in, I don’t think we’re going to see one on the way [out]. We think healthcare spending correlates much tighter on unemployment rates and the economy than necessarily to this kind of policy change.” —C.R. Bard CEO Timothy Ring, Jan. 26

Donald Trump: 5 questions medtech needs to ask>>

Pages: 1 2 3 4 5 6 7 8

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.